

Raluca Ionescu-Ittu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/809430/publications.pdf>

Version: 2024-02-01

30
papers

343
citations

933447

10
h-index

839539

18
g-index

30
all docs

30
docs citations

30
times ranked

702
citing authors

#	ARTICLE	IF	CITATIONS
1	Healthcare resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14366.	3.0	8
2	Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease in the U.S. Real-World Settings. <i>Rheumatology and Therapy</i> , 2022, 9, 265-283.	2.3	1
3	Disease Management and Outcomes in Patients Hospitalized for Acute Heart Failure in Japan. <i>Cardiology and Therapy</i> , 2021, 10, 211-228.	2.6	6
4	HSR21-063: Treatment Patterns Among Patients With EGFR Mutated Metastatic NSCLC Who Have Discontinued EGFR-TKI and Platinum-Based Chemotherapy Regimens. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, HSR21-063.	4.9	0
5	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <i>Advances in Therapy</i> , 2021, 38, 4520-4540.	2.9	32
6	Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 480-490.	1.9	11
7	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 2907-2921.	2.4	12
8	Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States. <i>Pediatric Rheumatology</i> , 2021, 19, 143.	2.1	1
9	In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. <i>JACC: Heart Failure</i> , 2020, 8, 943-953.	4.1	26
10	The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data. <i>Advances in Therapy</i> , 2020, 37, 4709-4719.	2.9	5
11	Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. <i>Epilepsia Open</i> , 2019, 4, 581-592.	2.4	19
12	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33.	0.5	6
13	Work productivity loss in patients with tenosynovial giant cell tumors in the United States.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22527-e22527.	1.6	2
14	Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. <i>Lung Cancer</i> , 2018, 119, 112-119.	2.0	11
15	Overall survival in patients with glioblastoma before and after bevacizumab approval. <i>Current Medical Research and Opinion</i> , 2018, 34, 813-820.	1.9	31
16	Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication. <i>BMC Infectious Diseases</i> , 2018, 18, 438.	2.9	8
17	Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 196-196.	1.6	0
18	Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210.. <i>Journal of Clinical Oncology</i> , 2018, 36, 496-496.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective.. Journal of Clinical Oncology, 2018, 36, 92-92.	1.6	0
20	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. Clinical Lung Cancer, 2017, 18, 640-650.e2.	2.6	5
21	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplantation, 2016, 22, 446-458.	2.4	73
22	Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 157, 145-156.	2.5	16
23	Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. SpringerPlus, 2016, 5, 395.	1.2	11
24	Overall survival in patients with glioblastoma before and after bevacizumab approval.. Journal of Clinical Oncology, 2016, 34, 2062-2062.	1.6	2
25	Access to biomarker testing in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e20655-e20655.	1.6	0
26	Access to specialist care and treatment in patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 9094-9094.	1.6	0
27	Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. Journal of the American Academy of Dermatology, 2015, 72, 968-977.e2.	1.2	43
28	Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab+carboplatin+paclitaxel and carboplatin+paclitaxel: A retrospective cohort study. Lung Cancer, 2014, 86, 350-357.	2.0	11
29	Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.. Journal of Clinical Oncology, 2014, 32, e11601-e11601.	1.6	1
30	Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up. Blood, 2013, 122, 4038-4038.	1.4	2